Skip to main content
Premium Trial:

Request an Annual Quote

NCATS Skeptics

The US National Institutes of Health has fielded a lot of skepticism regarding the National Center for Advancing Translational Sciences. Many in the research and funding communities say drug discovery is best left to pharmaceutical and biotech companies and NIH should concentrate on its basic research mandate. As our sister publication GenomeWeb Daily News reported, NCATS recently signed a deal with three pharmaceutical companies to enable researchers to test drugs the companies discarded to see if they can be repurposed. Forbes contributor John LaMattina, former president of Pfizer R&D, is skeptical as to the chances of this program's success. "If pharmaceutical companies already have this covered, why are they agreeing to let the NIH have access to these compounds? Why not?" LaMattina says. "Basically, the NIH is providing free R&D for compounds that are no longer in development, despite the companies' best efforts. They have nothing to lose by letting the NIH sponsor this work." Maybe NIH will get lucky and find something, he adds, but even if that happens, this isn't really the best use of NIH's funding, given tight budgets.

At In the Pipeline, Derek Lowe says it's only a matter of time before everyone knows whether this project was a waste of time and money. However, he adds, even if NCATS succeeds in the drug discovery business, this isn't the most efficient way to do it. "I'd rather start with a compound that I know does what I want it to do, and then try to turn it into a drug (phenotypic screening)," Lowe says. "Starting with a compound that you know is a drug, but doesn't necessarily do what you want it to, is going to be tricky."

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.